Treatment for Peritoneal Mesothelioma
Treatment for peritoneal mesothelioma includes surgery and chemotherapy. The treatment plan is tailored to each individual based on factors such as cancer stage and overall health.
The first treatment option considered is cytoreduction surgery with heated intraperitoneal chemotherapy (HIPEC). If surgery is not possible, then patients can receive standard chemotherapy (through an IV). There are additional treatment options – such as immunotherapy or gene therapy – available through clinical trials.
The main surgery for peritoneal mesothelioma is cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC). Doctors may refer to it as HIPEC surgery. The surgery involves the removal of tumors from the abdomen and the use of a heated chemotherapy solution.
Cytoreduction/HIPEC Surgery
Cytoreduction/HIPEC Process
Cytoreduction/HIPEC surgery is an extensive cancer surgery. It often lasts up to 12 hours, and recovery lasts up to two months.
Cytoreductive surgery involves “debulking”, which is the medical term for removing all visible tumors and diseased tissue. Doctors also remove the omentum, which is a non-vital layer of fatty tissue in the abdominal cavity, and may remove the peritoneum, spleen or other non-vital organs if they show evidence of tumors.
Cytoreductive surgery is combined with heated chemotherapy to destroy microscopic cancer cells still present after debulking. This method is called heated intraperitoneal chemotherapy, or HIPEC. The combination of heat and chemotherapy can kill tumor cells.
The heated chemotherapy is delivered directly into the abdominal cavity, which allows for higher doses. Delivering the chemotherapy this way rather than through the bloodstream can avoid some common side effects of traditional chemotherapy.
Chemotherapy for peritoneal mesothelioma is a common treatment option. Chemotherapy can be used before or after cytoreduction surgery with HIPEC. It can also be used for patients who will not receive HIPEC surgery.
Chemotherapy for peritoneal mesothelioma is delivered into the patient’s bloodstream or directly into the abdominal cavity during surgery.
Patients usually receive a combination of pemetrexed and cisplatin, which are the chemotherapy drugs approved by the U.S. Food and Drug Administration for peritoneal mesothelioma. Other chemotherapy drugs are available for individual cases.
The combination of pemetrexed and cisplatin helped patients live 12.1 months longer on average compared to people who did not receive chemotherapy.
Immunotherapy for peritoneal mesothelioma is an emerging treatment option for patients. Doctors are testing immunotherapies in clinical trials. Using immunotherapy as a peritoneal mesothelioma treatment represents a significant advancement in personalized cancer care.
The type of immunotherapy showing the most promise is immune checkpoint inhibitors. Examples are pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy) and durvalumab (Imfinzi). These therapies help the immune system look for and fight cancer cells.
Doctors published a case report on a peritoneal mesothelioma patient treated with immunotherapy. Keytruda led to a complete response, and the patient reached four years cancer-free in 2024.
Palliative care for peritoneal mesothelioma is a treatment approach focusing on quality of life. Palliative care for mesothelioma manages symptoms and side effects to make patients more comfortable. This should be a priority for patients with all stages of cancer and throughout the treatment process.
Palliative care for peritoneal mesothelioma may include a procedure (paracentesis) to drain fluid from the peritoneum. As fluid builds in the lining of the abdomen, patients experience pain, discomfort and abdominal distention. Paracentesis can relieve this discomfort.
Other examples of palliative care for peritoneal mesothelioma are:
- Lower doses of chemotherapy
- Acupuncture
- Antinausea medications (antiemetics)
- Massage therapy
- Pain management medications (opioids and antidepressants)
- Hospice care (for end of life comfort and support for the patient and family)
Radiation therapy for peritoneal mesothelioma is rarely used. Doctors are concerned the radiation beams can affect some of the organs within the abdominal cavity and cause severe or life-threatening side effects.